Summary
Latest filing:
Erez Meltzer is Chief Executive Officer, Director of Nano-X Imaging Ltd. (NNOX). 4 SEC Form 4 filings on record, most recently on 16 September 2026. Most recent open-market trade: bought $7K of NNOX on 16 September 2026. Lifetime open-market purchases: $58K.
Recent Transactions
4Every recent SEC Form 4 transaction Erez Meltzer has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Erez Meltzer files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Dan S. Suesskind - $92K of NNOX open-market activity in the last 12 months
- Noga Kainan - $30K of NNOX open-market activity in the last 12 months
- Erez Alroy - $1K of NNOX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Erez Meltzer?
Erez Meltzer is a corporate insider, tracked as Chief Executive Officer, Director of Nano-X Imaging Ltd. (NNOX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Erez Meltzer submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Erez Meltzer been buying or selling stock?
Recorded transactions: 4 open-market purchases ($58K) and 0 open-market sales across all tracked filings.
Where can I see all of Erez Meltzer's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Erez Meltzer and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
